Headlines about Concert Pharmaceuticals (NASDAQ:CNCE) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.8093781392149 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news headlines that may have effected Accern’s rankings:

Concert Pharmaceuticals (NASDAQ:CNCE) opened at $26.58 on Thursday. Concert Pharmaceuticals has a 52 week low of $7.11 and a 52 week high of $26.94.

A number of research analysts have issued reports on CNCE shares. Zacks Investment Research raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 15th. ValuEngine raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Mizuho started coverage on Concert Pharmaceuticals in a research note on Thursday, October 26th. They issued a “buy” rating and a $23.00 target price for the company. TheStreet raised Concert Pharmaceuticals from a “d” rating to a “c+” rating in a research note on Wednesday, November 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of Concert Pharmaceuticals in a research note on Friday, October 20th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $23.00.

In other news, insider Value Fund L. P. Biotechnology acquired 331,916 shares of Concert Pharmaceuticals stock in a transaction dated Thursday, October 19th. The stock was bought at an average cost of $15.84 per share, with a total value of $5,257,549.44. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronald W. Barrett sold 14,156 shares of the company’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $24.70, for a total value of $349,653.20. Following the transaction, the director now directly owns 3,539 shares of the company’s stock, valued at $87,413.30. The disclosure for this sale can be found here. 10.10% of the stock is currently owned by insiders.

WARNING: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-concert-pharmaceuticals-cnce-share-price/1762488.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Insider Buying and Selling by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.